Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Sponsor
Canadian Cancer Trials Group
Study ID
NCT01622543
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.

Key Dates

First listed
Jun 19, 2012
Start date
Oct 26, 2012
Status verified
Mar 2020
Primary completion
Jan 18, 2017
Completion
Sep 12, 2018

Study Design

Enrollment
109 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Folfox plus Bevacizumab and Reolysin
  • Active Comparator: Folfox plus Bevacizumab

Primary Outcome Measure

Progression Free Survival [ Time Frame: 19 months ]

Related Studies